Stockscreener 앱 받기
3.92
6.67%
0.245
전일 마감가:
$3.675
열려 있는:
$3.77
하루 거래량:
43,186
Relative Volume:
1.53
시가총액:
$10.60M
수익:
-
순이익/손실:
$-10.69M
주가수익비율:
-0.5535
EPS:
-7.0818
순현금흐름:
$-9.07M
1주 성능:
+6.81%
1개월 성능:
-14.41%
6개월 성능:
-62.46%
1년 성능:
-50.85%
1일 변동 폭
$3.64
$3.95
1주일 범위
$3.60
$4.04
52주 변동 폭
$3.51
$43.50
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
3.92 | 10.60M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Intensity Therapeutics Inc (INTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Intensity Therapeutics Inc (INTS) Institutional Confidence - TradingKey
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intensity Therapeutics Inc (INTS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com Canada
Intensity Therapeutics shareholders approve board proposals at annual meeting - Investing.com
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting - TipRanks
Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections - Stock Titan
INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote - TradingView
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Shows Modest Decline, Holds Above Key SupportBear Flag - newsline.com
Intensity Therapeutics (INTS) Edges Lower as Stock Holds Near Key SupportIchimoku Kumo Break - newsline.com
Intensity_Therapeutics - Westfair Communications
Intensity Therapeutics (INTS) Slips 5.75% as Selling Pressure Intensifies Near Key Support LevelValue Stock Ideas - newsline.com
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's why - MSN
INTS | Intensity Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
INTS Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Surprise History - The Legal Advocate
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why - Yahoo Finance
INTS Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Shares Edge HigherRevenue Inflection Point - The Legal Advocate
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
How Intensity (INTS) talent strategy drives results | Q1 2026: Profit Exceeds ViewsAdjusted Earnings Analysis - Newser
Intensity Therapeutics (NASDAQ:INTS) Q1 2026 Results Show EPS Beat Despite No Revenue - ChartMill
8-K: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatemoomoo - Moomoo
Trial updates frame Intensity Therapeutics (NASDAQ: INTS) Q1 2026 loss - Stock Titan
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INTENSITY THERAPEUTICS ($INTS) Releases Q1 2026 Earnings - Quiver Quantitative
INTS Q1'26 Earnings: EPS estimate is (1.08) USD - TradingView
Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - newser.com
Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore
Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan
[ARS] INTENSITY THERAPEUTICS, INC. SEC Filing - Stock Titan
What Just Happened to Intra-Cellular Therapies (ITCI) Stock - Kavout
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):